Search Results 2061-2070 of 16021 for Epilepsy (Partial Onset)

1. Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas - Mayo Clinic

   Histologically confirmed relapsed (response to last treatment ≥ 6 months duration) or refractory (no response to last treatment or response duration < 6 months) ...

2. Neratinib +/- Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer - Mayo Clinic

   ... duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating ...

3. A Study of the Effectiveness of LY3314814 in Patients with Mild Alzheimer's Disease Dementia - Mayo Clinic

   Participation eligibility · Other dementias · Repetitive head trauma · Serious infection of the brain · Parkinson's disease · Epilepsy · Cervicocranial vascular ...

4. A Study of Deep Phenotyping in Patients With ALS - Mayo Clinic

   ... epilepsy. Dental fillings are permitted. Additional criteria for sites performing MRI cytography: Subjects who have a history of claustrophobia that cannot ...

5. Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy - Mayo Clinic

   Antiemetic drugs, such as palonosetron hydrochloride, ondansetron, and granisetron hydrochloride, may help lessen or prevent nausea and vomiting in patients ...

6. Study to Evaluate the Safety and Effectiveness of BMS-986036 in Adults with Nonalcoholic Steatophepatitis (NASH) and Compensated Liver Cirrhosis - Mayo Clinic

   ... duration of treatment (BMS-986036 or placebo) plus 5 half-lives of study medication (5 days) plus 30 days (duration of ovulatory cycle) for a total of 35 ...

7. A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer - Mayo Clinic

   This is a two arm Phase III trial in first and second-line HER2 negative patients with locally recurrent or metastatic breast cancer. The primary endpoint is ...

8. A Study to Evaluate the Use of a Novel Wearable Device for Temperature Monitoring in Cancer Patients Who Underwent Autologous Stem Cell Transplant - Mayo Clinic

   ... duration of the study; Subjects able to record body temperature per the protocol for the duration of the study. Exclusion Criteria: Subjects pregnant or ...

9. A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke (REvive) - Mayo Clinic

   Able to initiate study intervention within 25 hours of stroke onset - Determined by the investigator to not be eligible for recanalization thrombolysis or

10. Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis - Mayo Clinic

    This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.